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Introduction: Chronic obstructive pulmonary disease (COPD) is characterized by non-reversible
airflow limitation and systemic engagement. Bacterial colonization in the lungs is common in
COPD-patients and may be associated with frequent acute exacerbations. Pattern-recognition
receptors (PRRs), like Toll-like receptor 2 (TLR2), TLR4 and CD14 are expressed on most immu-
nologic active cell types and are most likely of importance in COPD patho-physiology.
Material and methods: Twenty smokers with and 20 without COPD and 20 healthy non-smokers
participated in the study. At two visits, induced sputum was collected after spirometry, blood
was sampled and bronchoscopy with bronchoalveolar lavage was performed. Expression of
TLR2, TLR4 and CD14 on different cell types and soluble receptors were assessed in the
different compartments.
Results: Expression of TLR2 was lower on sputum neutrophils and soluble TLR2 (sTLR2) was
higher in the supernatant in the COPD group, indicating a down regulation of TLR2 at the
transit from blood to sputum. Expression of CD14 on sputum neutrophils and gene expression
of CD14 on alveolar macrophages was up-regulated in the two smoking groups compared with
non-smokers. No differences between the groups were found regarding TLR4 expression.
Conclusions: Pattern-recognition receptors (PRRs), that are expected to make a first line of
defense against invading micro-organisms, are differently regulated in smokers with COPD
compared with smokers without airflow limitation and non-smokers. This is likely of impor-
tance in COPD patho-physiology, in particular for exacerbations, which often are caused by
micro-organisms.
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ska Institutet, AstraZeneca, Sweden.
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Innate immunity in smokers 1223Introduction found as mRNA and not as protein in humans.
10 SolubleChronic obstructive pulmonary disease (COPD) is a glob-
ally growing disease which is characterized by airway
inflammation and tissue destruction with non-reversible
airflow limitation. Today COPD is recognized as a systemic
disease, thus not solely affecting the airways and lungs.1
One of the main effector cells in COPD is the neutrophil
granulocyte and during exacerbations, which are often
caused by bacterial infections, neutrophils are rapidly
recruited to the site of action and have a substantial role
in tissue damaging and bacterial killing.2,3 Bacterial
colonization of the lungs is often reported in patients with
COPD, and is associated with frequent acute exacerba-
tions.4 There are a number of reports demonstrating that
COPD-patients have elevated numbers of neutrophils in
sputum and bronchoalveolar lavage (BAL)-fluid.5,6
Neutrophils together with other inflammatory active
cells interact with pathogen- and/or damage associated
molecular patterns (PAMPs and/or DAMPs). These are
sensed through highly conserved pattern-recognition
receptors (PRR), called Toll-like receptors (TLRs). Lipo-
proteins from Gram-positive bacteria are ligands for Toll-
like receptor 2 (TLR2) and TLR4 recognizes, together with
CD14, lipoproteins from Gram-negative bacteria. Signaling
through TLRs leads to activation of the NF-lB pathway and
formation and release of pro-inflammatory cytokines and
chemokines. Both TLR2 and TLR4 have been extensively
studied and seem to have both endogenous and exogenous
ligands.7 It has been shown that alveolar macrophages
from smokers with and without COPD express less TLR2
than non-smokers8 but the soluble forms of these recep-
tors (sTLR2, sTLR4 and sCD14) have, however, been
sparsely studied. Both sTLR2 and sTLR4 are believed to
have a regulating role as decoy receptors in host innate
immune response against microbial pathogens, resulting
in a negative regulation of cytokines and chemokines.
Soluble TLR2 is found in human plasma, breast milk and
saliva and has the potential to modulate phagocytosis and
superoxide production9; whereas sTLR4 has only beenTable 1 Subject characteristics. Data are presented as mean a
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DLCO (mmol/kPa/min) 25 (CD14 has a dualistic effect; on one hand sCD14 mediates
the activation of membrane-negative CD14 cells, on the
other hand it serves as a decoy receptor, by competing
with mCD14 for LPS thereby reducing LPS-triggered
activities. Soluble CD14 is also known to increase in serum
during inflammatory conditions as an acute phase
protein11 and are elevated in bronchoalveolar lavage
(BAL) fluid from smokers with and without COPD.12,13
The aim of this study was to find out whether the
expression of innate immunity receptors on inflammatory
cells are altered in smokers with and without COPD
compared with non-smokers, and whether possible alter-
ations are present already on circulating cells or if
possible alterations occur when the cells enter the
airways. Therefore, inflammatory cell expression of TLR2,
TLR4 and CD14 and soluble TLR2 and CD14 were assessed
in blood, bronchoalveolar lavage fluid (peripheral
airways) and induced sputum (central airways) from
smokers with and without COPD and in healthy non-
smokers.Material and methodsSubjects and study design
Twenty non-smoking healthy controls, 20 current smokers
with normal spirometry and 20 current smokers with COPD
were recruited from primary and secondary care at Kar-
olinska University Hospital and by advertisement in the
daily press. Smokers were included in the COPD group if
post-bronchodilator FEV1/FVC was <0.70, post-bronchodi-
lator FEV1 was 40e70% of predicted value and arterial
oxygen saturation (SaO2) > 90%. Smokers were allocated to
the non-COPD group if they had post-bronchodilator FEV1/
FVC > 0.70 and FEV1 >80% of predicted value. The control
group consisted of healthy non-smoking subjects with
normal spirometry. Subject characteristics are displayed in
Table 1. Subjects with a history of asthma or othernd 95% confidence intervals (CI). FVC: Forced Vital Capacity,
lue, DLCO: Carbon Monoxide Diffusing Capacity.
-smoking
trols
20
Smokers with
COPD
n Z 20
Smokers without
COPD
n Z 20
51e59) 62 (59e65) 56 (53e59)
15/5 11/9
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0 n Z 20 n Z 20
0 n Z 9 n Z 0
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(0.77e0.83) 0.54 (0.50e0.58) 0.75 (0.72e0.78)
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1224 I. von Scheele et al.pulmonary diseases or allergic diseases were excluded from
the study, as were COPD-patients who have had an exac-
erbation within the last month prior to the study.
Spirometry was performed according to current guide-
lines (ATS/ERS)14 and diffusion capacity (transfer factor,
DLCO) was performed using carbon monoxide single breath
technique.15 Induced sputum and bronchoscopy including
bronchoalveolar lavage (BAL) were performed on two sepa-
rate days. Blood samples were drawn on the bronchoscopy
day. All subjects gave their informed consent and the study
was approved by the ethics committee at the Karolinska
Institutet, Stockholm Sweden (Dnr 2005/733-31/1-4).
Sputum induction and processing
Sputum induction and processing were performed as
previously described.16 The cell pellet was re-suspended in
2 ml PBS and put on ice until antibody staining for the flow
cytometry analysis. A total cell count and viability test with
Trypan blue were performed. Cytocentrifuge-prepared
slides were stained with May-Gru¨nwald Giemsa stain and
300 cells (squamous cells excluded) were assessed for
differential cell counts. The sputum samples were included
in the analysis if they contained less than 30% squamous
cells. The supernatant was dispensed into aliquots and kept
in 70 C until analysis.
BAL-fluid and alveolar macrophage isolation
Bronchoscopy was performed as previously described.17
After pre-medication with scopolamine, analgesics and
local anesthesia with xylocain the bronchoscope was
wedged in a middle lobe segmental bronchus and 5 aliquots
of 50 ml isotonic saline were instilled into the airway tree
and gently sucked back. The lavage fluid was centrifuged
and the supernatant was dispensed into aliquots and kept in
70 C until analysis.
Approximately 2 million cells/well were then re-sus-
pended in RPMI-cell medium supplemented with 10% serum.
After 2 h the macrophages were presumed to be adhered.Figure 1 Leucocytes in blood and sputum analyzed by flow cyto
differential cell count (A). Induced sputum, double stained with ant
surface expression on neutrophils of the receptor of interest (B).The supernatant was discarded and PBS was added to the
macrophages in order to perform mRNA preparation.
Blood
Whole peripheral blood was collected in ethylene diamine-
tetra-acetic acid (EDTA) vacutainer tubes (BD Bioscience,
New Jersey, USA). The cells were stained for specific anti-
bodies (TLR2, TLR4 and CD14) for further FACS analysis, but
also analyzed in Attractors (BD Bioscience, San Jose, CA,
USA) to perform a five-part white blood cell differential, as
previously described.18 The tests were performed within 2 h
after sampling.
Flow cytometry (FACS)
To analyze the expression of TLR2, TLR4 and CD14 on
sputum neutrophils and blood neutrophils and monocytes,
100,000 sputum cells or 100 ml of whole blood, were incu-
bated with 10 ml monoclonal antibodies for 30 min (anti-
TLR2-PE clone TL2.1, anti-TLR4-PE clone HTA125, anti-
CD14-FITC clone 61D3, 10 mg/ml, eBioscience, San Diego,
CA, USA). Anti-CD45 and SSC (Side Scatter) were used for
gating cells both in blood and sputum (Fig. 1). Anti-CD66
was used to further identify neutrophils in sputum. Sputum
cells were incubated on ice and blood cells in room
temperature. As negative controls, isotype-matched anti-
bodies were used. After incubation the cells were washed
twice and re-suspended in PBS. Analyses were performed
using FACSCalibur and median fluorescent intensity (MFI)
was determined by CELLQuest (BD Bioscience Pharmin-
gen) and calculated as relative median fluorescence
intensity (rMFI Z monoclonal antibody/corresponding iso-
type control).
mRNA preparation and real-time PCR
Preparation of mRNA from alveolar macrophages was per-
formed in ten subjects from each group. The alveolarmetry. Leucocytes stained with anti-CD45 in blood, to perform
i-CD45 and anti-TLR2, or anti-TLR4 or anti-CD14 to measure cell
Table 2 Differential cell count in blood, BAL-fluid and induced sputum. Data are presented as median (25e75th percentiles).
P-values indicate differences compared with controls and significant differences are indicated in “bold”. P < 0.05 are
considered significant and n.s. indicates non significant.
Non-smoking
controls
Smokers with
COPD
Smokers without
COPD
Blood (103 cells/mL)
n Z 16e18
Neutrophils 2785 (2104e4283) 4072 (3618e5392)
PZ0.012
3684 (3003e4312)
n.s.
Monocytes 465 (360e630) 666 (516e801)
n.s.
620 (532e711)
n.s.
Lymphocytes 1769 (1647e2404) 2212 (1942e2661)
PZ0.041
2281 (1852e3161)
PZ0.027
Basophils 56 (46e67) 91 (64e113)
PZ0.018
74 (59e104)
PZ0.030
Eosinophils 158 (111e247) 254 (236e334)
n.s.
280 (135e369)
n.s.
BAL-fluid (106 cells/L)
Cell viability 96% (95e97)
n Z 13e18
Total cells 125 (87e147) 324 (173e455)
PZ0.0002
302 (246e457)
P< 0.0001
Neutrophils 3 (1e5) 7 (2e20)
PZ0.045
8 (4e15)
PZ0.017
Macrophages 108 (78e122) 266 (144e402)
PZ0.0003
272 (221e422)
P< 0.0001
Lymphocytes 6 (4e14) 10 (3e20)
n.s.
11 (8e18)
n.s.
Basophils 0 (0e0) 0 (0e0)
n.s.
0 (0e0)
n.s.
Eosinophils 0 (0e0) 4 (1e12)
PZ0.001
1 (0e2)
n.s.
Sputum (cells/mg sputum)
Cell viability 92% (82e96)
n Z 10e13
Total cells 1265 (1011e2220) 1580 (1350e7383)
n.s.
2190 (1610e3000)
n.s.
Neutrophils 220 (122e472) 530 (316e1430)
PZ0.013
311 (132e592)
n.s.
Macrophages 286 (122e563) 195 (131e358)
n.s.
186 (89e385)
n.s.
Lymphocytes 17 (6e30) 15 (8e64)
n.s.
8 (6e11)
n.s.
Basophils 0 (0e0) 0 (0e0)
n.s.
0 (0e0)
n.s.
Eosinophils 0 (0e0) 8 (2e23)
PZ0.006
2 (0e4)
n.s.
Innate immunity in smokers 1225macrophages were washed twice with PBS and total mRNA
was isolated by PureLink Micro-to Midi Total RNA Purifi-
cation System (Invitrogen). DNase I, amplification grade
was used to remove genomic DNA (Invitrogen). First-strand
cDNA was synthesized from 0.5 mg of total RNA, using
QuantiTect Reverse Transcription Kit (Qiagen, Hilden,
Germany). Real-time PCR was performed using an ABI
Power SYBR Green Master mix (Applied Biosystems) with
TLR2, TLR4 and CD14 primers, 1 ml of cDNA was amplified in
25 ml PCR reaction to identify the products of interest. Beta
actin was used as an internal control gene. The primers
were designed with the software Primer3 and purchased
from Invitrogen.
Data were analyzed using 7500 Software v.2.0.1 (Applied
Biosystem) and transformed using the DCt-method
(DCtZ the difference in threshold cycles for the test gene
and beta actin). The results were then calculated and
expressed as 2DCt.Soluble CD14 and TLR2
Soluble human CD14 (sCD14) and soluble TLR2 (sTLR2) were
measured in the supernatants from BAL-fluid and sputum
with purchased DuoSet ELISA CD14 kit and DuoSet ELISA
sTLR2 kit (R&D Systems, Europe, Abingdon, UK). The anal-
yses were performed according to manufacturer’s protocol
and the detection range was 62.5e4000 pg/ml and
125e8000 pg/ml for sCD14 and sTLR2, respectively. For
duplicate samples an intra-assay coefficient of variation
(CV) < 15% was accepted.Endotoxin
The concentration of endotoxin was analyzed in BAL-fluid
using a kinetic technique of Limulus amebocyte lysate
assay according to the manufactures instructions, the
Figure 2 Surface expression of TLR2 on blood and sputum neutrophils, analyzed by flow cytometry. Data obtained from the same
subject are connected with a line. Significant differences between compartments are stated with a p-value and between groups
with a bracket (A). Toll-like receptor 2 expression on blood monocytes, measured by flow cytometry (B). Gene expression of TLR2 in
alveolar macrophages, measured by real-time PCR (C). Soluble TLR2 in BAL-fluid supernatant, measured by ELISA (D). Soluble TLR2
in sputum supernatant measured by ELISA (E). P < 0.05 are considered significant.
1226 I. von Scheele et al.samples were diluted in endotoxin specific buffer
(Limulus Amebocyte lysate, Endosafe Endochrome-K
U.S. Lisence No. 1197, Coatech AB, Kungsbacka, Sweden)
and Escherichia coli 0111:B4 was used as standard.Statistics
Results are presented as scattergram, medians and inter-
quartile ranges or as means and 95% confidence intervals.
Comparisons between the groups were performed by
KruskaleWallis (KeW) test followed by ManneWhitney
U-test if the p < 0.05 in the KeW test. Within group
comparisons were performed using Wilcoxon signed rank
test. All data were analyzed by StatView version 5.0.1 (SAS
Institute Inc., Cary, NC). A P-value< 0.05 was considered
significant.Results
Due to technical problems with FACS-antibodies, difficulties
in receiving adequate sputum or enough cells and problems
related to bronchoscopy, datasets are not complete with
regard to all outcome variables. Numbers of analyses are
indicated in the figures.Cell differential count in blood, BAL-fluid and sputum
The concentration of neutrophils was higher in the COPD
group than in controls in blood, BAL-fluid and induced
sputum (Table 2) and higher in BAL-fluid from smokers with
normal spirometry compared with controls. The concen-
tration of macrophages was elevated in BAL-fluid from the
two smoking groups compared with the healthy controls. In
blood, an increased concentration of both lymphocytes and
basophiles was observed in the two groups of smokers
compared with the control group. The concentration of
eosinophils was increased in both BAL-fluid and sputum
from COPD-patients compared to controls (Table 2) and was
higher in BAL-fluid in the COPD group compared with
smokers with normal spirometry (p Z 0.032).
Toll-like receptor 2 (TLR2)
Toll-like receptor 2 expression on blood neutrophils did not
differ between the three groups. Expression of TLR2 on
sputum neutrophils was significantly lower in COPD-
patients than in the control group (KruskaleWallis
p Z 0.016, ManneWhitney p Z 0.012). The expression of
TLR2 on neutrophils was significantly lower in sputum than
in blood in both groups of smokers (p < 0.05, Fig. 2A).
Figure 3 Surface expression of TLR4 on blood and sputum neutrophils, measured by flow cytometry. Data obtained from the same
subject are connected with a line. Significant differences between compartments are stated with a p-value (A) and between groups
with a bracket. Toll-like receptor 4 expression on blood monocytes, measured by flow cytometry (B). Gene expression of TLR4 in
alveolar macrophages, measured by real-time PCR (C). Endotoxin in BAL-fluid supernatant, measured by kinetic-LAL assay (D).
Innate immunity in smokers 1227Expression of TLR2 on blood monocytes and mRNA
expression of TLR2 in macrophages obtained from BAL-fluid
did not differ between the groups (Fig. 2B, C).
Soluble TLR2 (sTLR2) in the BAL-fluid was higher in the
controls than in COPD (KruskaleWallis p Z 0.023, Man-
neWhitney pZ 0.005, Fig. 2D). In sputum sTLR2 was higher
in COPD than in controls (KruskaleWallis p Z 0.013, Man-
neWhitney p Z 0.012) and smokers without COPD
(p Z 0.011 Fig. 2E).
Toll-like receptor 4 (TLR4) and endotoxin
The TLR4 expression on neutrophils was enhanced in
sputum compared with blood in the control group.
(p Z 0.018, Fig. 3A). The TLR4 expression on neutrophils
(blood and sputum) and monocytes (blood) and the gene
expression of TLR4 in alveolar macrophages did not differ
significantly between the three groups (Fig. 3AeC).
The endotoxin level in BAL-fluid supernatant was higher
in the control group than in smokers without COPD (Krus-
kaleWallis p Z 0.002, ManneWhitney p Z 0.017) and
COPD-patients (p Z 0.001, Fig. 3D).
CD14
The CD14 expression on blood and sputum neutrophils did
not differ between the three groups. There was a significantincrease of CD14 expression on sputum neutrophils
compared to blood neutrophils in both groups of smokers
(p < 0.05, Fig. 4A) whereas no significant differences were
found on blood monocytes (Fig. 4B). In BAL-fluid macro-
phages CD14 mRNA expression was elevated in both groups
of smokers compared to the controls (KruskaleWallis
p Z 0.004, ManneWhitney p  0.010, Fig. 4C).
Soluble CD14 (sCD14) did not differ significantly
between the groups, neither in BAL-fluid nor in sputum
(Fig. 4D, E).Discussion
In this report it was demonstrated that TLR2 expression is
reduced on sputum neutrophils from patients with COPD
compared with non-smokers, and that the expression of
TLR2 on neutrophils is higher in blood than in sputum,
irrespective of the presence of airway obstruction.
Furthermore, for the first time it was shown that COPD was
associated with higher levels of soluble TLR2 (sTLR2) in
sputum and lower levels of sTLR2 in BAL-fluid compared
with non-smokers. We also demonstrated that the expres-
sion of CD14 on neutrophils was enhanced in sputum
compared with blood and that that the gene expression of
CD14 on alveolar macrophages in BAL-fluid was increased in
smokers compared with non-smokers. In addition, COPD-
Figure 4 Surface expression of CD14 on blood and sputum neutrophils, measured by flow cytometry Data obtained from the same
subject are connected with a line. Significant differences between compartments are stated with a p-value (A) and between groups
with a bracket. Expression of CD14 on blood monocytes, measured by flow cytometry (B). Gene expression of CD14 in alveolar
macrophages, measured by real-time PCR (C). Soluble CD14 in BAL-fluid supernatant, measured by ELISA (D). Soluble CD14 in
sputum supernatant measured by ELISA (E).
1228 I. von Scheele et al.patients exhibited neutrophilia compared with non-smokers
in all three compartments, i e sputum (central airways),
BAL-fluid (small airways) and in blood (systemically).
Down regulation of TLR2 has previously been demon-
strated on alveolar macrophages from smokers8 and on
blood monocytes from non-smoking farmers19; who, like
smokers, are continuously exposed to organic material. In
our study we did not found expression of TLR2 on circula-
tion monocytes to be altered, which is in agreement with
the study by Droemann et al.8 but in contrast to the study
of Pons et al.20 who found up regulation of TLR2 on circu-
lation monocytes from COPD-patients. The explanations to
these discrepancy findings are unclear.
From the present data it is clear that TLR2 receptors are
down regulated on airway neutrophils in COPD and that this
down regulation takes place during the transition from
blood to the airways. In this respect, smokers without COPD
hold a position in between, as the TLR2 expression on
neutrophils was clearly elevated in blood compared with
sputum whereas no difference in sputum neutrophil TLR2
expression was found between smokers with normal
spirometry and non-smokers. The two smoking groups were
matched with regard to cumulative exposure to tobacco
smoke, which indicates that the susceptibility to tobacco
smoke and the development of COPD seems to constitute
a “constitutional” difference between smokers who do and
do not develop COPD. A potential weakness of this finding isthe problem of power; few observations of this parameter
make firm conclusion uncertain.
Neutrophils participate in the first line of airway defense
and TLR2 on the cell surface of the neutrophils are
responsible for binding of microbial products, mainly from
Gram-positive bacteria, in order to reduce and eliminate
harmful influences of the exposure. The finding of
decreased TLR2 expression on sputum neutrophils and
increased levels of sTLR2 in sputum in COPD strongly
suggest a shedding of the TLR2 in smokers who have
developed COPD while no such shedding was observed in
smokers with normal spirometry. Thus, receptor shedding
does not seem to be a consequence of chronic exposure, as
the cumulative exposure to tobacco smoke was similar in
smokers with and without COPD. It might rather be an
effect of bacterial colonization in patients with COPD
causing an increased microbial burden, and possible lead to
receptor shedding in order to counteract the chronic
inflammation. The mechanisms of receptor down regulation
and shedding are unclear as is the patho-physiological
implications. The difference between the two groups of
smokers, who had similar exposure to tobacco smoke but
different clinical phenotypes, is of great interest and is
likely of importance in the pathogenesis of COPD.
The novel finding that surface expression of TLR2 on
neutrophils is attenuated on the transit from blood to
sputum indicates that TLR2 expression is tightly regulated
Innate immunity in smokers 1229and that a first line regulatory mechanism occurs. This
finding is also in line with a previous report of a lower
expression of TLR2 on alveolar macrophages than on blood
monocytes.8,21 On the other hand, in asthmatics, whose
cellular phenotype is dominated by neutrophils, increased
TLR2 gene expression was found on sputum cells22; which
likely could be a consequence of treatment with inhaled
steroids as previous in vitro experiments have demonstrated
that the gene expression on TLR2 is up-regulated by
steroids.23
Neutrophils are the dominating cells in sputum, thus the
neutrophils are, most likely, the primary source of sTLR2
found in sputum of patients with COPD. In BAL-fluid, where
the presence of neutrophils is less abundant and the
number of macrophages is high, the amount of sTLR2 was
lower in the COPD group than in the non-smokers. A
possible explanation to this is that sTLR2 in BAL-fluid might
origin from the macrophages, explaining the inversed
pattern observed between sputum and BAL-fluid.
In the present study subjects with reversible airway
obstruction or a history of asthma and allergy were excluded.
Thus, the finding of increased concentration of eosinophils in
BAL-fluid and sputum in the COPD group was not associated
with co-existing asthma. From previous studies it is clear that
eosinophilia is observed in somepatientswithCOPD24,25 and it
iswell documented that airway eosinophilia occurs in relation
to acute exacerbations.26
The alteration of different innate immunity receptor
expression during the transition from blood to the airways
does not follow the same pattern, while TLR2 expression on
neutrophils attenuates, TLR4 and mCD14 increase. This
indicates different regulating mechanisms for different
PRRs. The findings suggest an up regulation of TLR4 and
CD14 as a result of stimulation when reaching the airways,
and are in line with reported elevated expression of mCD14
on macrophages from induced sputum in COPD-patients.27
The differences between PRR-regulation patterns upon
pro-inflammatory stimulation may be a result of the
receptors’ ability to shed. The soluble form of TLR2 (sTLR2)
is present in human plasma, saliva, BAL-fluid and sputum9;
whereas sTLR4 only are found as mRNA in human and not as
a protein.10 This explanation might even account for the
elevated expression of mCD14 in sputum neutrophils
compared to the expression on blood neutrophils. Even
though sCD14 is highly present in both central airways
(sputum) and small airways (BAL-fluid) it is known to be
even higher in serum. This might indicate less shedding of
mCD14 locally (in the airways) than systemically (in the
blood), resulting in an elevated mCD14 expression on
sputum neutrophils compared to blood neutrophils.
In spite of the fact that we found an elevated mRNA
expression of CD14 in alveolar macrophages obtained from
BAL-fluid in smokers with and without airway obstruction,
we were not able to detect higher amounts of sCD14 in BAL-
fluid. As smokers are exposed to endotoxin through ciga-
rette smoke28 it is tempting to speculate that sCD14 had
bind to its ligand, LPS (endotoxin), which also may explain
the finding of lower levels of soluble endotoxin in super-
natants from BAL-fluid in both groups of smokers compared
with the non-smoking control group.
In summary our results support the hypothesis that
pattern-recognition receptors are modulated in COPD. Wesuggest that a diminished TLR2 expression on airway inflam-
matory cells leads to reduced pathogen identification and
removal which, in turn, facilitate bacterial colonization and
increases the risk of exacerbations in COPD. Our findings also
highlight how tightly regulated the expression of these
receptors are, which may be crucial for the defense of the
host.
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